12/8/2003

Drugmaker Johnson & Johnson announced it has received FDA approval for its schizophrenia drug, Risperdal, to treat bipolar I disorder, the most severe form of the disease. The company said users of the drug showed significant improvement over persons treated in a control group.

Full Story:
NYTimes.com

Related Summaries